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http:WHAT THIS PAPER ADDS
Six quality indicators of peripheral artery disease based on strong recommendations and high methodological
evidence have been deﬁned. These indicators could play a key role in assessing the appropriateness of
healthcare provided to patients with this disease, with respect to pharmacological and lifestyle issues.Objectives: Peripheral artery disease (PAD) is a major health problem whose clinical management includes
multiple options regarding risk factor control, diagnosis, and medical and surgical treatment. The aim was to
generate indicators based on systematic reviews to evaluate the quality of healthcare provided in PAD.
Methods: Electronic searches were run for systematic reviews in The Cochrane Library (Issue 6, 2011), MEDLINE,
EMBASE, and other databases (up to June 2011). Conclusive systematic reviews of high methodological quality
were selected to formulate clinical recommendations. Indicators were derived from clinical recommendations
with moderate to very high strength of evidence as assessed by the GRADE system.
Results: From 1,804 reviews initially identiﬁed, 29 conclusive and high-quality systematic reviews were selected
and nine clinical recommendations were formulated with a moderate to very high strength of recommendation.
Six indicators were ﬁnally generated: four on pharmacological interventions, antiplatelet agents, naftidrofuryl,
cilostazol, and statins; and two lifestyle interventions, exercise and tobacco cessation. No indicators were derived
for diagnostic tests or surgical techniques. Most indicators targeted patients with intermittent claudication.
Conclusions: These quality indicators will help clinicians to assess the appropriateness of healthcare provided in
PAD. The development of evidence-based indicators in PAD is limited by the lack of methodological quality of the
research in this disease, the inconclusiveness of the evidence on diagnostic and surgical techniques, and the
dynamic nature of the vascular diseases ﬁeld.
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The Institute of Medicine (IOM) deﬁnes quality of health-
care as “the degree to which health services for individuals
and populations increase the likelihood of desired health
outcomes and are consistent with current professional
knowledge”.1 Quality of care can be measured by deriving
indicators for each of its main components: structure,
processes and outcomes.2 The indicators of processes are
more clinically speciﬁc, easier to interpret, and more sen-
sitive to differences than indicators of structure and out-
comes.3,4 Process indicators are direct measures of the
quality of care provided when there is a link between aresponding author. S. Bellmunt, Sant Antoni Maria Claret, 167 Bloc
Floor, 08025 Barcelona, Spain.
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//dx.doi.org/10.1016/j.ejvs.2014.02.001given process and outcome of interest. If there is no evi-
dence that a given process is closely related to an outcome,
there is no justiﬁcation for the use of a process indicator.3
Evidence about any possible linking between process and
outcome comes from the analysis and synthesis of the
literature. Process indicators commonly aim to measure
adherence to clinical practice guidelines (CPGs) in clinical
practice.5,6 The American College of Cardiology and the
American Heart Association developed a structured meth-
odology to create performance measures through a
sequence of tasks.6 This process considers critical issues
such as the strength of evidence, the clinical relevance of
the outcome, and the magnitude of the relationship be-
tween performance and outcome. This methodology uses
clinical recommendations of CPGs as a source of evidence
to generate performance measures to assess the quality of
care in acute coronary syndrome,7 cardiac failure,8 and
atrial ﬁbrillation and atrial ﬂutter.9
Table 1. General structure of a quality indicator.
Item Description Source of information
a. Title Brief statement of what is to be assessed Research team
b. Type of indicator  Process indicator
 Indicator of desirable or undesirable events
 Indicator based on proportions or means
Clinical recommendation
based on SR
c. Deﬁnitions Clinical recommendation (PICO format): Clinical
situation, population, intervention, comparison
and main outcomes.
 Deﬁnition of contraindications to treatment
(if necessary)
 Description of the diagnostic and procedure
codes ICD-9-CM for the identiﬁcation of the
population.
Clinical recommendation
based on SR, ICD-9-CM
d. Target population Deﬁnition of the target population Clinical recommendation
based on SR
e. Rationale  Impact of the clinical condition of interest
 Brief description of the selected systematic
review
 Summary of the main beneﬁts and/or harms
associated with the intervention
SR, CPG
f. Supporting literature Main bibliography that supports the indicator
(SR  CPG)
SR, CPG
g. Description of indicator population Operational deﬁnition of the indicator (formula).
 Numerator/denominator
 Exclusion criteria
Clinical recommendation
based on SR, clinical experts
h. Sources of information Description of the sources of information to
compute the indicator:
 Administrative databases (mainly from
inpatient and surgical area)
 Clinical documentation (medical history)
 Other (e.g. survey)
Clinical experts
i. Standard Deﬁnition of the standard:
 Desirable event ([)
 Undesirable event (Y)
Clinical recommendation
based on SR
j. Underlying factors  Factors related to the target population
 Factors related to professionals
 Factors related to the hospital
SR, CPG, Clinical experts
k. Notes Other aspects that complement the information
summarized by the indicator
Clinical experts
l. Desired characteristics of a hospital
to ensure the viability of the indicator
 Essential features (associated with the
identiﬁcation of the denominator and
the numerator)
 Desirable features (associated with
an acceptable time investment to
measure it)
Clinical experts
Note. SR ¼ systematic review; ICD-9-CM ¼ International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation; CPG ¼ clinical
practice guideline.
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applied in the ﬁeld of obstetrics to generate healthcare
process indicators based on good-quality systematic re-
views.10 Healthcare process indicators could be useful in
many specialties, particularly those where different diag-
nostic or therapeutic criteria are available to manage the
same disease, such as vascular pathology. Peripheral artery
disease (PAD) is an important disease within the vascular
ﬁeld because it is prevalent in all developed countries and
is a strong risk marker for cardiovascular events and
mortality.11,12 The appropriate clinical approach to PAD
aims to decrease cardiovascular morbidity and mortality,
reduce the risk of amputation, and increase patients’
functional status and quality of life.13e16 It is necessary to
ensure the quality of patient care through quality in-
dicators based on interventions supported by strong evi-
dence. Such evidence could be derived from the numerous
systematic reviews on diagnosis and therapy for PAD.
Nevertheless, process indicators based on systematic re-
views are lacking in PAD.
The aim of this study was to develop a set of process
indicators based on systematic reviews to evaluate the
appropriateness of healthcare provided in PAD.METHODS
A comprehensive search of systematic reviews (SRs) and
clinical practice guidelines (CPGs) in PAD was conducted.
The search terms: peripheral arterial disease [Mesh], pe-
ripheral vascular diseases [Mesh] and peripheral arterial
disease, peripheral vascular disease, and intermittent clau-
dication were used as keywords or as a part of title or
abstract.
To be included, the SR of peripheral artery disease had
to be quantiﬁable and related to therapeutic or diagnostic
interventions. The electronic search was conducted in
the following databases: the Cochrane Database of
Systematic Reviews and the Database of Abstracts of
Reviews of Effects (The Cochrane Library, Issue 6, 2011),
Clinical Evidence, MEDLINE, EMBASE (OVID), and meta-
searchers such as NHS Evidence, Excelencia Clínica and
TRIP Database. The databases were searched up to June
2011.
CPGs in vascular disease were searched to identify
additional SRs cited on their references. The search for
recent CPGs was conducted in MEDLINE, EMBASE, NHS
Evidence, and Trip Database (published between 2006 and
2011). The guidelines published by the main vascular sur-
gery societies and organizations that produce CPGs were
also consulted: the National Institute for Clinical Excellence
(NICE), National Guideline Clearinghouse, and Guia Salud.
Duplicate references and those which were not in English
or Spanish were discarded.
Two authors (DO and HP) independently examined the
retrieved systematic reviews and selected those with strong
conclusions for or against a particular intervention. The
selection process was performed by consensus. In case of
disagreement, a third author (MR) was consulted.Methodological quality was then evaluated according to
SIGN criteria,17 which assess ﬁve internal validity criteria:
clear formulation of the question, description of the meth-
odology used, comprehensive search strategy, assessment of
the quality of studies included in the SR, and assessment of
the heterogeneity of the included studies. SRs with an
overall positive assessment of the internal validity criteria
were selected. When two or more SRs assessed the same
intervention, that with the highest validity from among the
most recent SRs was selected.
Two researchers (DO, and HP or MR) generated clinical
recommendations (CRs) from selected SRs. All CRs included
an intervention, a target population of the intervention, and
the effects of the intervention on outcomes of interest. The
quality and strength of evidence supporting each CR was
evaluated with an adaptation of the GRADE system.18 The
quality and strength of evidence was rated as very high,
high, moderate, low, or very low. Only those CR rated as
very high, high, or moderate were selected as the basis for
building indicators. The generation and selection of CRs was
also performed by consensus and with the agreement of
two expert vascular surgeons (SB and JE).
The methodology for developing indicators has been
described previously.10 From the selected CR, indicators
were constructed using an adaptation of the method pro-
posed by the American College of Cardiology/American
Heart Association (ACC/AHA),6 and the Agency for Health-
care Research and Quality (AHRQ).19 Table 1 shows the
general structure of an indicator. Most of the information
presented in an indicator was derived from the SR, but
additional information was drawn from current guidelines
and the clinical expertise provided by two clinical experts
(SB and JE). Feedback from these surgeons was used to
identify the validity of each indicator, sources of clinical data
needed to compute each indicator, causes of variability in
results, and characteristics of a clinical setting that ensure
viability of the indicator.
RESULTS
Results of the search
The initial search in electronic databases yielded 1,804 SR
and 940 CPGs (Fig. 1). After applying the selection pro-
cess, 27 SRs with consistent results and of high meth-
odological quality (Table 2) were indentiﬁed. By using the
GRADE system seven moderate or high CRs were ob-
tained, based on eight of these reviews.20e27 Feedback
from vascular surgeons led to the discarding of a CR
about materials used in bypass surgery,25 because it
generated an indicator of little clinical relevance. Finally,
six quality indicators related to PAD were generated; part
of their structure (title, clinical recommendation, rational
and standard) is described below. The rest of the struc-
ture is presented in Tables 3e5, grouped by topic: anti-
platelet treatment (Table 3), lifestyle (Table 4), and other
drugs (Table 5). All six indicators describe a desirable
event and higher values indicate more appropriate
performance.
800 duplicated between 
databases:
148 COCHRANE
292 EMBASE
73 Excelencia clínica
106 NHS
55 MEDLINE
126 Tripdatabase
1004 references screened
66 COCHRANE
325 EMBASE
5 Excelencia clinica
106 NHS
420 MEDLINE
82 Tripdatabase
27 SR of good quality assessed with GRADE 
Database searching of Systematic Reviews 
(SR): 1804 references 
214 COCHRANE
617 EMBASE
78 Excelencia clínica
212 NHS
475 MEDLINE
208 Tripdatabase
748 SR excluded
(Language, title or abstract) 
-113 did not follow the methodology of 
a SR 
71 CPG
6 new SR identified 
from CPG
8 SR included used to generate indicators
19 SR lead to weak recommendations 
(See Table 2)
Additional search: 
Clinical Practice 
Guidelines (CPG): 
940 references 
869 excluded: 
648 duplicated between 
databases
221 (Language, title or 
abstract) 
(See also Table 2)
-86 had no strong conclusion 
-36 had poor methodology according 
to SIGN or SR of studies included in 
other more updated SR (13 and 23
respectively).
262 Full-text articles
assessed for eligibility
Figure 1. Flow diagram. Note. SR ¼ systematic review; CPG ¼ clinical practice guideline.
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Proportion of patients with intermittent claudication to
whom antiplatelet therapy is prescribed. Deﬁnition: If a
patient has intermittent claudication, then an appropriate
antiplatelet agent should be administered, unless it is
contraindicated, because antiplatelet agents have been
shown to reduce cardiovascular mortality and the need for
revascularization.
Evidence description: Two systematic reviews of good
quality20,23 showed beneﬁts with antiplatelet use. Wong
et al.23 (3,926 patients) compared antiplatelet agents (thie-
nopyridine derivatives) versus placebo and found lower
mortality for all causes (RR 0.76; 95% CI 0.60e0.98) and less
revascularization (RR 0.65; 95% CI 0.43e0.97).23 In thesecond review, including 6,263 intermittent claudication pa-
tients, the Trialists’ Collaboration group concluded that an-
tiplatelet agents caused an odds reduction of major
cardiovascular events of 23% compared to placebo.20 Addi-
tionally, in an evidence-based guideline,15 the authors rec-
ommended either aspirin or clopidogrel as the antiplatelet
agent of choice for PAD patients, based on evidence from
patients with cardiovascular disease or at high vascular risk.
Proportion of patients with a history of bypass grafting to
whom antiplatelet agents are prescribed. Deﬁnition: If a
patient has peripheral artery disease and a history of bypass
grafting, then an appropriate antiplatelet should be admin-
istered, unless it is contraindicated because antiplatelet
agents have shown higher graft patency at 12 months.
Table 2. Distribution of systematic reviews throughout the selection process (grouped by intervention categories).
Intervention Strong conclusions SIGN þþ/
Not replaced by newer
SRa
CR moderate, high or
very high (modiﬁed
GRADE)
No
(N ¼ 86)
Yes
(N ¼ 63)
No
(N ¼ 36)
Yes
(N ¼ 27)
No
(N ¼ 19)
Yes
(N ¼ 8)
A. Diagnosis (4) (15) (9) (6) (6) (0)
Ankleebrachial index 1 2 2 0 0 0
Ultrasonography 0 2 2 0 0 0
CT angiography 1 2 2 0 0 0
Magnetic resonance angiography 0 5 2 3 3 0
Treadmill 0 1 1 0 0 0
Clinical examination 0 1 0 1 1 0
Spectroscopy 1 0 0 0 0 0
C-reactive protein 1 0 0 0 0 0
Various diagnostic procedures 0 2 0 2 2 0
B. Pharmacological treatment (27) (29) (17) (12) (7) (5)
Antithrombotics (various) 3 6 3 3 3 0
Antiplatelets 4 11 5 6 3 3
Anticoagulants 1 1 1 0 0 0
Thrombolytics 2 3 2 1 1 0
Prostanoids 2 2 2 0 0 0
Vasodilators (various) 3 1 0 1 0 1
Buﬂomedil 1 1 1 0 0 0
Naftidrofuryl 1 1 1 0 0 0
Antihypertensives (various) 1 0 0 0 0 0
Beta-blockers 2 1 1 0 0 0
ACEI 1 0 0 0 0 0
Lipid-lowering statins 1 1 0 1 0 1
Homocysteine lowering 2 0 0 0 0 0
Sexual hormones 1 0 0 0 0 0
Various drugs 2 1 1 0 0 0
C. Surgical treatment (26) (4) (2) (2) (1) (1)
Amputation 3 0 0 0 0 0
Angioplasty 17 3 2 1 1 0
Bypass 4 1 0 1 0 1
Various surgical procedures 2 0 0 0 0 0
D. Lifestyle (9) (7) (3) (4) (2) (2)
Exercise 6 4 2 2 1 1
Smoking cessation 0 1 0 1 0 1
Diet/glucose control 2 1 0 1 1 0
Various lifestyles interventions 1 1 1 0 0 0
E. Other interventions (18) (8) (5) (3) (3) (0)
Brachytherapy 1 1 1 0 0 0
Stem cell 1 0 0 0 0 0
Alternative/complementary medicinesb 7 2 2 0 0 0
Sympathectomy/spinal cord stimulation 3 1 0 1 1 0
Pneumatic leg compression 2 1 0 1 1 0
Gene therapy 2 1 0 1 1 0
Dressings for leg ulcers 1 0 0 0 0 0
Prevention of infection 0 1 1 0 0 0
Physical rehabilitation 0 0 0 0 0 0
Chelation therapy 1 1 1 0 0 0
F. Treatment in general 1 0 0 0 0 0
G. Diagnosis and treatment in general 1 0 0 0 0 0
Note. SR ¼ systematic review; CR ¼ clinical recommendation; ACEI ¼ angiotensin-converting enzyme inhibitors.
a SR whose studies were included in other more updated SR were discarded.
b Includes: acupuncture, biofeedback, chelation therapy, CO2-applications and dietary supplements: garlic, ginkgo, omega-3 fatty acids and
vitamin E.
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Table 3. Description of the indicators related to antiplatelet treatment (indicators 1 and 2).
Indicator 1 Indicator 2
a. Title Proportion of patients with intermittent
claudication to whom antiplatelet agents are
prescribed
Proportion of patients with history of bypass
grafting to whom antiplatelet agents are
prescribed
b. Type Process indicator about a desirable event based on proportions
c. Other deﬁnitions Contraindications to treatment: familial or
acquired bleeding disorder, thrombocytopenia,
allergy, active bleeding or lesions likely to bleed,
within 72 hours of major surgery with risk of
severe bleeding, severe renal or hepatic
impairment or other contraindications known
Diagnostic and procedure codes. Peripheral
vascular disease, unspeciﬁed (ICD-9-CM
Diagnosis Code 443.9)
Contraindications to treatment. Familial or
acquired bleeding disorder, thrombocytopenia,
allergy, active bleeding or lesions likely to bleed,
within 72 h of major surgery with risk of severe
bleeding, severe renal or liver impairment or
other contraindications known
Diagnostic and procedure codes. Resection Of
Vessel With Anastomosis, Lower Limb Arteries
(ICD-9-CM Procedure Code 38.38); Resection Of
Vessel With Replacement, Lower Limb Arteries
(ICD-9-CM Procedure Code 38.48); Other Excision
Of Vessels, Lower Limb Arteries (ICD-9-CM
Procedure Code 38.68)
d. Target population Patients with peripheral artery disease and
intermittent claudication
Patients with peripheral artery disease and
history of bypass grafting
e. Description of
indicator population
Numerator ¼ number of patients who receive
aspirin (75 or 100 mg/day) or clopidogrel (75 mg/
day) or ticlopidine 250 mg/day)
Denominator ¼ number of patients with
peripheral artery disease and intermittent
claudication
Exclusion criteria ¼ exclude from denominator
those patients with any contraindication to
aspirin, clopidogrel or ticlopidine
Numerator ¼ number of patients who receive
aspirin (75 or 100 mg/day) or clopidogrel (75 mg/
day) or ticlopidine 250 mg/day)
Denominator ¼ number of patients with
peripheral artery disease and history of bypass
grafting
Exclusion criteria ¼ exclude from denominator
those patients with any contraindication to
aspirin, clopidogrel or ticlopidine
f. Sources of information  Clinical documentation (medical history)
 Administrative databases
 Clinical documentation (medical history)
 Administrative databases
g. Setting characteristics Good clinical documentation and pharmacy
record
Good clinical documentation and surgery records
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quality22 with 966 patients undergoing infrainguinal
bypass surgery compared antiplatelet agents (ASA and/or
dipyridamol) versus placebo, another antiplatelet agent or
an alternative treatment. It found a beneﬁt in graft
patency at 12 months compared to no treatment in pa-
tients with peripheral bypass (OR 0.59; 95% CI 0.45e0.79).
This beneﬁt was greater in the subgroup of patients with
an artiﬁcial graft (OR 0.22; 95% CI 0.12e0.38) than in the
subgroup of patients with a vein graft (OR 0.69; 95% CI
0.48e0.99).
Proportion of patients with intermittent claudication to
whom an exercise routine is prescribed. Deﬁnition: If a
patient has peripheral artery disease and intermittent
claudication, then an exercise routine appropriate for the
patient’s health status should be prescribed, because ex-
ercise beneﬁts walking time and distance.
Evidence description: A systematic review of good qual-
ity26 compared exercise regimens versus placebo, pharma-
cological treatment, or surgery. Compared with placebo,
exercise improved maximal walking time (255 patients;
improvement of 5.12 minutes; 95% CI 4.51e5.72), pain-free
walking distance (322 patients; improvement of 82.19 m;
95% CI 71.73e92.65), and maximum walking distance (391patients; improvement of 113.20 m; 95% CI 94.96e131.43).
Improvements were seen for up to 2 years. Evidence for the
comparison of exercise and pharmacological and surgical
treatments was weak because the comparisons included a
small number of trials and participants.
Proportion of current smokers with a history of bypass
grafting, to whom a tobacco cessation intervention is
prescribed. Deﬁnition: If a patient with a history of bypass
grafting currently smokes, then a tobacco cessation interven-
tion should be prescribed, because continued smoking after
lower limb bypass surgery increases the risk of graft failure.
Smoking cessation, even when started after the operation,
could restore graft patency to that of never smokers.
Evidence description: A systematic review of good qual-
ity27 with 1,198 patients compared graft patency between
smokers and non-smokers. It showed a threefold greater
risk of graft failure in smokers than in non-smokers (RR 3.09;
95% CI 2.34e4.08).
Proportion of patients with intermittent claudication, with
no control of symptoms, to whom naftidrofuryl or cil-
ostazol is prescribed. Deﬁnition: If a patient has peripheral
artery disease and intermittent claudication, and his or her
symptoms are not controlled, then naftidrofuryl or cilostazol
Table 4. Description of the indicators related to lifestyle (indicators 3 and 4).
Indicator 3 Indicator 4
a. Title Proportion of patients with intermittent
claudication to whom an exercise routine is
prescribed
Proportion of current smokers, with history of
bypass grafting, to whom a tobacco cessation
intervention is prescribed
b. Type Process indicator about a desirable event based on proportions
c. Other deﬁnitions Contraindications to treatment. Exercise routine
must be appropriate for each case
Diagnostic and procedure codes. Peripheral
vascular disease, unspeciﬁed (ICD-9-CM
Diagnosis Code 443.9)
Contraindications to treatment. Tobacco
cessation intervention must be appropriate for
each case
Diagnostic and procedure codes. Resection Of
Vessel With Anastomosis, Lower Limb Arteries
(ICD-9-CM Procedure Code 38.38); Resection Of
Vessel With Replacement, Lower Limb Arteries
(ICD-9-CM Procedure Code 38.48); Other Excision
Of Vessels, Lower Limb Arteries (ICD-9-CM
Procedure Code 38.68)
d. Target population Patients with peripheral artery disease and
intermittent claudication
Patients with peripheral artery disease and
history of bypass grafting
e. Description of
indicator population
Numerator ¼ number of patients with an
appropriate exercise routine prescribed
Denominator ¼ number of patients with
peripheral artery disease and intermittent
claudication
Exclusion criteria ¼ None
Numerator ¼ number of patients with an
appropriate intervention for tobacco cessation
prescribed
Denominator ¼ number of patients with
peripheral artery disease and history of bypass
grafting
Exclusion criteria ¼ None
f. Sources of information  Clinical documentation (medical history)
 Administrative databases
 Clinical documentation (medical history)
 Administrative databases
g. Notes None Advice for tobacco cessation should be given to
every patient. However, we consider that
measuring this indicator in all population could
be difﬁcult; so patients with history of bypass
grafting were prioritized
h. Setting characteristics Good clinical documentation (medical history) Good clinical documentation and surgery record
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this medication has been shown to increase maximal and
pain-free walking distance.
Evidence description: A health technology assessment
systematic review of good quality24 presented evidence on
naftidrofuryl and cilostazol. Meta-analysis of 1,479 patients
with intermittent claudication estimated that, compared to
placebo, cilostazol increased maximal walking distance by
57.27 m (95% CI 24.93e86.57). Network meta-analyses
estimated that both naftidrofuryl and cilostazol signiﬁ-
cantly increased maximal walking distance and pain-free
walking distance.
Proportion of patients with peripheral artery disease to
whom a statin is prescribed. Deﬁnition: If a patient has
peripheral artery disease, then a statin should be pre-
scribed, because these agents reduce revascularization and
cardiovascular morbidity.
Evidence description: A systematic review of good qual-
ity21 included trials comparing lipid-lowering therapy versus
placebo. It showed that lipid-lowering therapy reduced the
risk of total cardiovascular events (9,120 patients: OR 0.74;
95% CI 0.55e0.98) and revascularization (7,102 patients; OR
0.73 95% CI 0.64e0.83).DISCUSSION
A systematic search and analysis of available literature to
identify interventions for peripheral artery disease sup-
ported by strong evidence, in order to generate healthcare
quality indicators was conducted. The available evidence
generated four indicators on pharmacological interventions,
antiplatelets, naftidrofuryl, cilostazol, and statins, and two
lifestyle interventions, exercise and tobacco cessation.
It was not possible to obtain any indicators about diag-
nostic tests or surgical techniques because there were no
studies with strong conclusions or the quality of such
studies was low. It is surprising that no strong evidence was
found to support consolidated revascularization techniques
widely used in clinical practice. There are several possible
explanations. Researchers may consider it unethical to
compare the effectiveness of widely accepted techniques
such as limb bypass against medical treatment or placebo.
Another possibility is that the rapid development of new
endovascular techniques and materials could lead to a lack
of studies with a sufﬁcient number of cases and of an
acceptable quality. It is less surprising that solid evidence on
less studied and experimental interventions for PAD such as
genetic therapy, stem cell, brachytherapy, arterial ulcer
Table 5. Description of the indicators related to the use of other drugs (indicators 5 and 6).
Indicator 5 Indicator 6
a. Title Proportion of patients with intermittent
claudication, with no control of symptoms, to
whom naftidrofuryl or cilostazol is prescribed
Proportion of patients with peripheral artery
disease to whom a statin is prescribed
b. Type Process indicator about a desirable event based on proportions
c. Other deﬁnitions Contraindications to treatment: Known
hypersensitivity to cilostazol or to naftidrofuryl;
severe renal or hepatic impairment; congestive
heart failure; pregnancy; known predisposition to
bleeding; history of heart arrhythmia or history of
hyperoxaluria or recurrent calcium stones or
other contraindications known
Diagnostic and procedure codes. Peripheral
vascular disease, unspeciﬁed (ICD-9-CM
Diagnosis Code 443.9)
Contraindications to treatment: Hypersensitivity
to statins; active liver disease or unexplained
persistent isolated elevations of serum
transaminases; pregnancy or lactation or other
contraindications known
Diagnostic and procedure codes. Peripheral
vascular disease, unspeciﬁed (ICD-9-CM
Diagnosis Code 443.9)
d. Target population Patients with peripheral artery disease and
intermittent claudication
Patients with peripheral artery disease
e. Description of
indicator population
Numerator ¼ number of patients who receive
cilostazol or to naftidrofuryl
Denominator ¼ number of patients with
peripheral artery disease and intermittent
claudication
Exclusion criteria ¼ exclude from denominator
those patients with any contraindication to
cilostazol or to naftidrofuryl
Numerator ¼ number of patients who receive a
statin
Denominator ¼ number of patients with
peripheral artery disease
Exclusion criteria ¼ exclude from denominator
those patients with any contraindication to
statins
f. Sources of information  Clinical documentation (medical history)
 Administrative databases
 Clinical documentation (medical history)
 Administrative databases
g. Setting characteristics Good clinical documentation and pharmacy
record
Good clinical documentation and pharmacy
record
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are still under debate was not found.
An additional contribution of this study is the quality
assessment it provides on the systematic reviews carried
out to date in this ﬁeld. PAD has been extensively
researched and is the subject of many systematic reviews,
but a great percentage of these have poor methodological
quality. Better research practices need to be implemented
to optimize human and monetary resources invested in
research.28 Implementing sound methodological practices
in systematic reviews may help to design better and more
conclusive clinical trials.
The continuous innovation in the ﬁeld of peripheral ar-
tery disease makes it difﬁcult to develop evidence-based
indicators of quality that are relevant to clinical practice.
When high-quality evidence becomes available for a given
intervention, clinical practice may have changed. A good
example is the clinical recommendation that was rejected in
this study, namely prioritizing Dacron grafts over PTFE in
limb revascularization. The choice between these two graft
materials was controversial only a few years ago, while now
the dilemma is whether limb revascularization should be
performed with open surgery or by endovascular
techniques.14
The strength of evidence observed in the present study is
similar to that in CPGs about PAD.13,14 As in this study,
these guidelines based most recommendations regardingrevascularization or diagnostic techniques on a low level
evidence14 and most recommendations regarding pharma-
cological and lifestyle interventions were based on sound
evidence.13e15 However, healthcare quality indicators go a
step further than clinical recommendations in CPGs because
they are based on clinical practices that are almost
mandatory.
Healthcare quality indicators can only be based on rec-
ommendations in CPGs that explicitly mention and assess
the sources and quality of the evidence. A good example is
the work by Alonso et al. 2012,15 where evidence tables are
provided applying the GRADE system. In the present study,
the availability of such recommendations for PAD would
have eliminated the need to search for and assess sys-
tematic reviews to deﬁne clinical recommendations.
In a study similar to this, published in 2010, the authors
developed a set of seven performance measures for adults
with PAD.16 Their methodology was based on translating
guideline recommendations Class I and Class III and expert
opinion into process measures. The performance measures
which were developed concerned ankle brachial index (ABI)
measurement, use of cholesterol-lowering medications,
administration of antiplatelet therapy, smoking cessation,
prescription of supervised exercise, graft surveillance (with
ABI and duplex ultrasound), and monitoring of abdominal
aortic aneurysms. Although they were similar, the two
projects had marked differences. First, the scope of the
68 S. Bellmunt et al.disease differed, because this work was restricted to lower
limb PAD, excluding abdominal aortic aneurysms and ca-
rotid disease. Second, the evidence threshold established in
their project was lower, because their Class I and Class III
recommendations were based on single randomized clinical
trials. The evidence on ABI measurement and duplex ul-
trasound, for example, emanated from single trials. Finally,
the fact that they included expert opinion also led to dif-
ferences between their performance measures and these.
For example, they recommended antiplatelet therapy in
critical limb ischemia on the basis of indirect evidence from
patients with intermittent claudication or other cardiovas-
cular diseases.
This study has limitations concerning its design and the
applicability of the indicators. First, the indicators generated
do not incorporate patient preferences and costs, possibly
limiting their usefulness. Neither do they take into account
the commercial distribution of some drugs, such as cil-
ostazol, which is only available in ﬁve countries in Europe,
limiting the applicability of the indicator. Furthermore, the
use of a ﬁlter to discard systematic reviews without strong
conclusions for or against a particular intervention is
debatable because it could introduce bias by discarding
more recent or high-quality SRs. Difﬁculties applying the
GRADE system to assess diagnostic techniques were also
encountered as it was not designed to assess such clinical
questions.
In conclusion, six quality indicators were deﬁned, based
on strong recommendations and high methodological evi-
dence. These indicators could play a key role in assessing
the appropriateness of health care provided to patients
with PAD concerning pharmacological and lifestyle issues.
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